Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report and Form 10K
Dyadic International, Inc. has reached its limit for free report views.
Work for Dyadic International, Inc.?
Claim Your Profile
Dyadic International, Inc.
About Dyadic International, Inc.
1-10 Employees
Based in Jupiter, Florida
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.
- Ticker:
- DYAI
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
